Advertisement

ASCO GI 2023

Zolbetuximab Plus mFOLFOX6 Scores in Gastric Cancer

Jan 27, 2023

REFERENCES & ADDITIONAL READING

  1. Shitara K, et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. Late-breaking abstract 292, ASCO GI, 19–21 January, San Francisco, CA, USA.

ABOUT THE CONTRIBUTORS

Author

Advertisement

All our ASCO GI 2023 features in one convenient place! ASCO GI Cancer 2023.indd

Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement